

# FOLLOW-UP MEETING ON THE PUBLIC CONSULTATIONS ON BPA




Comments on EFSA's draft  
assessment of human health risks  
from the UK Committee on Toxicity

*presented by Prof Rob Smith,  
'public interest' member of COT*

# Terms of reference of the COT

- To advise at the request of all Government Departments and Agencies
- To assess and advise on toxic risk to man of substances, including:
  - food additives and other chemicals with potential to be present in food
  - in workplace
  - in consumer products
  - chemicals with potential to pollute the environment
- To advise on generic principles and emerging issues




# COT membership

- 16 specialist members
  - endocrinology, epidemiology, exposure assessment, immunology, medicine, molecular biology, neurotoxicology, nutrition, pathology, pharmacokinetics, pharmacology, reproductive toxicology, risk assessment, statistics, toxicology,
- 2 non-specialist members
  - consumer and public interest
- We are all independent members



# Response by COT to draft scientific opinion on human health risks of BPA


- 
- Impressive document overall
  - COT generally agreed with conclusions
  - *Not clear whether this part of opinion will be merged with exposure part*
  - *If not, need diagrams of chemical structure of BPA and metabolites*
  - Specific comments that follow relate to sections 2, 3, 4 and 8

## Section 2. Methodology

- Support weight of evidence approach
- *Classification system a little unusual*
- *Do not like the phrase “as likely as not” where evidence is inadequate*
- *Prefer “inadequate evidence” as descriptor*
- *Need to emphasise that classification relates to hazard identification, not risk assessment*



# Section 3. Hazard identification

- 
- Conclusions regarding epidemiological data are appropriate
  - *Some queries about weight given to different sorts of study*
  - *Would be helpful to provide confidence intervals when summarising results*
  - *Need to clarify argument about reliability of studies involving serum samples*

## 3.1. Toxicokinetics and metabolism

- COT endorsed EFSA's use of human equivalent dose (HED)
- *No information in this part of opinion on chemistry of bisphenol A, which is pertinent to the PBPK model*



## 3.2. General toxicity

- COT agreed that liver and kidney effects were “likely”
- *Noted that hypertrophy is likely to be an adaptive rather than toxic response*


## 3.3. Reproduction/development

- COT broadly agreed that effects on fetal growth and thyroid function were “not likely”
- *Needs to be more discussion about discrepancies between studies*



# Sections 3.4 - 3.7

COT agreed that the following effects were “not likely” overall:

- 
- Neurological and neuroendocrine
  - Immunological
  - Cardiovascular
  - Metabolic
  - *However the description of some epidemiological studies was unclear*

## Sections 3.8 - 3.9

COT agreed that the following effects were “not likely”:

- Genotoxicity
- Carcinogenicity

COT agreed that effects on mammary gland proliferation or differentiation were “likely” but that the implications were unclear.

## Section 4. Health-based guidance value

- COT considered the proposed temporary tolerable daily intake to be appropriate
- *Some queries about the modelling*
- *Need further discussion about elements of the total uncertainty factor*



# Section 8. Recommendations

COT supported the need for

- Further good-quality research on possible non-monotonic dose-response relations for bisphenol A
- Further work on dermal absorption and metabolism of dermally absorbed BPA
- Toxicokinetics of BPA in humans *as well as* in mice



COT public documents can be found at:  
<http://cot.food.gov.uk/>



Thank you